Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

This study is specifically designed for children who have already completed one of two previous studies involving dasiglucagon: studies ZP4207-17103 or ZP4207-17109. This means your child would have already received this treatment and been closely monitored.

To join this long-term study, the doctors involved must believe that dasiglucagon continues to be helpful for your child, and that the benefits outweigh any potential risks. They will look at how the treatment has affected your child's blood sugar, how well they tolerated it, and any side effects they might have experienced in the earlier study.

Your child cannot join this study if they developed any new health problems, needed new medicines that were not allowed in the previous studies, or if their doctor feels there are other reasons why taking part would not be safe or suitable for them.

If your child is eligible and you decide to take part, they will continue to receive dasiglucagon as an infusion given under the skin. As this is an extension study, the exact details of visits and assessments will be tailored to what's needed for long-term monitoring, building upon what was learned in the previous studies. This will involve regular check-ups with the study doctors and nurses, where they will monitor your child's blood sugar levels, overall health, and any side effects. You will be given clear instructions on how to administer the dasiglucagon at home and what to do in case of any concerns. The total duration for how long each child will stay in this study has not been specified, but it's designed to be a longer-term observation.